Press releases

10-15-2003

curasan AG among the "Fast 50"

Deloitte & Touche honours Germany's high-growth companies

Kleinostheim/Düsseldorf, 15 Oct. 2003 - The selection of Germany's fastest growing technology companies has been made. curasan AG, an enterprise specialising in Regenerative Medicine, has been recognised as one of the most successful players within the marketplace. The company was listed in 33rd place by the international auditing and consulting group Deloitte & Touche as part of its "Fast 50" ranking of fast-track enterprises. Over the past five financial years (1998 - 2002), curasan AG achieved accumulated revenue growth of 203 per cent.

The top fifty companies were present at yesterday's official award ceremony held in the atrium of Deloitte & Touche's new "Spherion" office complex in Düsseldorf. Dr. Theo Waigel, Germany's former Federal Minister of Finance also attended the top-class event. The Technology Fast 50 Award has become well established in a number of countries around the world. It is presented in recognition of the accomplishments of high-growth companies within the areas of IT, Communication and Life Sciences, in particular those which have achieved top-class performances thanks to initiative, innovatory prowess, professionalism within their field of expertise, and the willingness to take commercial risks.

"This award pays tribute to curasan as one of the fastest growing companies in Germany within the area of Life Sciences," says Hans Dieter Rössler, CEO of curasan AG. "We remain committed to above-average growth in the future and are well positioned both strategically and financially following the sale of our pharmaceuticals unit and the focus on Regenerative Medicine with biomaterials."

While Cerasorb Ortho™ has recently been launched in the US, distribution of the newly developed Cerasorb® Paro has now commenced in Europe. This product is targeted specifically at applications within the area of periodontology. Additional product modifications developed in close cooperation with end-users are currently in the pipeline and are to be rolled out over the coming months.